The trial investigated the efficacy and safety of pembrolizumab in combination with pemetrexed and platinum chemotherapy versus pemetrexed and platinum chemotherapy for the treatment of patients ...

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is ...

Details concerning the Pemetrexed medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, and injections.

lung cancer Pemrydi RTU is expected to be available in the first quarter of 2024. The Food and Drug Administration (FDA) has approved Pemrydi RTU ® (pemetrexed injection), a ready-to-use (RTU ...

Pemetrexed is used to treat certain types of cancer (such as lung cancer and mesothelioma). It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells. Pemetrexed is ...

The FDA has approved a generic form of the intravenous chemotherapy pemetrexed for use by itself in patients with locally advanced or metastatic non-squamous non-small cell lung cancer that has not ...

“Previously, sintilimab in combination with pemetrexed and a platinum-based chemotherapy had shown promising activity for nonsquamous non-small cell lung cancer in a phase 1b study. Based upon ...

Pemetrexed-based chemotherapy regimens were more effective as treatment of patients with&nbsp;<em>RET</em>-rearranged non&ndash;<a>small</a>&nbsp;cell lung cancer ...

The FDA has been granted to Pemfexy™ (pemetrexed for injection; Eagle Pharmaceuticals), an alternative to Alimta® (Eli Lilly), for the treatment of non-small cell lung cancer (NSCLC ...

05, assuming that median OS values were 13 and 16.5 months in the single-agent bevacizumab and pemetrexed plus bevacizumab arms, respectively (HR, 0.787). One-sided tests were performed for OS as a ...

A randomized, phase 2 trial of carboplatin plus pemetrexed (Alimta, Eli Lilly) with or without pembrolizumab showed significantly better rates of response and longer progression-free survival with ...